Introduction
Low-dose-rate brachytherapy has been used in the treatment of low-, intermediate-and high-risk prostate cancer in combination with androgen deprivation therapy (ADT) and/ or supplemental external beam radiation therapy (EBRT) [1] [2] [3] [4] [5] . The American Brachytherapy Society consensus guidelines recommend monotherapy brachytherapy in low-risk patients but regimens for intermediate-risk patients are less well defined [6] . Recently, the Radiation Therapy Oncology Group (RTOG) conducted a randomized study of patients with prostate cancer with one intermediate-risk factor treated with implant only or implant and EBRT [7] . Their results indicated equivalence in freedom from biochemical failure (FfBF), overall survival, distant metastasis rate, and prostate cancer-specific mortality. Acute overall toxicity in the two groups was similar; however, grade 3 or higher genitourinary, gastroinstestinal and overall late toxicity were higher in the combination therapy arm of the study.
Comparisons of treatment methods in intermediate-risk patients have been impeded by inconsistent criteria for defining intermediate risk. Additionally, within the accepted risk stratification groups, there exists considerable heterogeneity. For example, an analysis of 12 821 patients showed that those assigned to the intermediate-risk group by clinical stage (T2b-T2c) had a lower risk of recurrence than those categorized according to Gleason score (7) or PSA level (10-20 ng/mL) [8] .
In the present study, we undertook a review of patients with intermediate-risk prostate cancer to compare implant vs combined brachytherapy and EBRT in a mature dataset with regard to toxicities. We also examined cancer control outcomes in patients with any number of intermediate-risk features and sub-classified the study population into men with one risk feature and men with multiple risk features to better understand each group.
We anticipate that the findings from the present study will improve management of patients receiving radiation therapy treatment for intermediate-risk prostate cancer, especially patients with multiple intermediate-risk features, and contribute to establishing a 'gold standard' of treatment for these patients.
Materials and Methods

Patient Selection
A total of 3 874 men were treated for prostate cancer with brachytherapy at our institution since 1990 and consented to have their information stored in an institutional review board-sanctioned database. Of these patients, 902 had one or more intermediate-risk features but no high-risk features, and at least 24 months of follow-up. A total of 521 patients were classified as intermediate risk according to the National Comprehensive Cancer Network classification guidelines, which define intermediate risk as having one of the following features: PSA 10-20 ng/mL; Gleason score 7; or stage T2b or T2c [9] . An additional 381 patients had prostate cancer with two or three intermediate-risk factors.
Patient Characteristics
The median (range) age for the 902 patients in the present study was 68 (44-85) years. The median (range) pre-implant prostate volume was 33 (8.40-188.10) cm 3 . Patient and disease characteristics are listed in Table 1 .
Treatment
Treatment consisted of either low-dose-rate brachytherapy implant, or implant combined with EBRT. All patients were implanted transperineally using a real-time ultrasonographyguided technique, which has been previously described [10] . EBRT techniques evolved over time starting with six-field three-dimensional conformal techniques to six-field static field intensity-modulated radiation treatments and then to rotational intensity-modulated radiation arc therapy. Treatments were provided with or without the addition of ADT. Implants alone were carried out using All treatments were performed by a single practitioner (R.S.). The standard field included the prostate and seminal vesicles with 1-2-cm margins. Pelvic lymph nodes were not treated prophylactically but rather, were only treated when known to be positive. Typically, the brachytherapy implant occurred 6 weeks before the start of EBRT. The normal tissue constraints included rectal and urethral dose, keeping rectal v100 below 1 cm 3 with implant procedure, as well as D30 of urethra ≤150% of the prescription dose for the implant.
Hormonal therapy was used in some patients as adjuvant therapy to improve cancer control. It was also used for patients with prostate volumes >60 cm 3 . Of the 902 patients, 622 (69%) were on ADT, which consisted of an LHRH agonist (leuprolide acetate or goserelin acetate) with or without the addition of an antiandrogen (flutamide or bicalutamide) for 3 months before brachytherapy and a median of 3 months after. Those with multiple intermediaterisk factors were more likely to receive ADT. Of the 521 patients with one intermediate-risk factor, 320 (61.4%) received ADT. Of the 314 with two risk factors and the 67 patients with three risk factors, 241 (76.8%) and 61 (91%) received ADT, respectively.
Post-Implant CT Dosimetry and Biologically Effective Dose Calculations
Within 1 month after implantation, all patients underwent post-implant dosimetric analysis using CT technology. All doses were represented by the D90 planning dose and were converted to BED using a previously described formula with prostate carcinoma constants a/b = 2 Gy [11] . The median (range) calculated BED was 199 (15.1-299.2) Gy 2 . In the present study, the patient population was divided into two BED groups based on a cutoff point of 150 Gy. These thresholds were set based on previously established clinically meaningful BED divisions [11] . Total BED consisted of the implant alone or the sum of the partial implant plus the EBRT dose. In all, 84 patients received a BED <150 Gy, referred to as low dose in the present study, 769 patients received a BED >150 Gy and 49 patients (5.4%) did not have recorded BED data because of inability to perform postimplant dosimetry in patients with bilateral hip prosthesis and because some patients did not return for post-implant dosimetry follow-up.
Follow-up and Treatment Endpoints
Patients were requested to return for follow-up visits every 6 months. Overall, the median (range) follow-up time was 91 (23-261) months. Cancer control endpoints were based on the most recent follow-up visit. The endpoints used in the present study were biochemical failure (defined according to the Phoenix definition) [12] , and distant metastases as determined by positive bone CT scan. Toxicities were measured using the IPSS, Sexual Health Inventory for Men (SHIM), RTOG rectal bleeding scale, and Mount Sinai erectile function scale, which has been previously described [13] . Patients were also asked at every visit if they experienced urge or stress incontinence (measured by pad use), urinary retention (defined as requiring a Foley catheter), haematuria or dysuria.
Statistical Methods
Endpoints including biochemical failure, death and metastases were calculated using actuarial methods and Kaplan-Meier survival curves were compared using log-rank tests. Univariate analyses were performed to examine toxicities and demographic variables. Multivariate analyses were performed using the Cox Regression model, with stepwise selection and a significance level of 0.2 to enter or leave the model. Variables considered in the multivariate analysis included treatment group, BED, ADT, stage, Gleason score, age, number of intermediate-risk features, race and initial PSA level. Toxicities were compared between groups using crosstabs Pearson chi-squared tests. ANOVA tests were also carried out. P values ≤0.05 were taken to indicate statistical significance. Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) software [14] .
Results
External Beam Radiation Therapy Effect on Cancer Control
The results of a univariate analysis comparing brachytherapy alone and brachytherapy combined with EBRT for biochemical failure (Table 2 ) and distant metastases showed few significant differences in outcomes between treatment groups. The only factor that was found to have a significant effect on biochemical failure was the use of ADT (P = 0.039); however, this effect disappeared in a univariate analysis when excluding patients who received low-dose (BED < 150 Gy) radiotherapy.
As Table 3 shows, in a multivariate analysis, continuous BED and ADT were associated with freedom from biochemical failure. There was no significant difference in mean high posttreatment testosterone levels between monotherapy (mean 406.12) and combination therapy (mean 424.65; P = 0.063).
In a univariate analysis, patients receiving brachytherapy monotherapy were significantly less likely to experience distant metastases if they received a BED > 150 Gy (P = 0.022), had a Gleason score of 7 (vs ≤6; P = 0.031), stage < T2b (P = 0.028), were on ADT (P = 0.017) or if they had one intermediate-risk feature (vs ≥two features; P = 0.047). In this analysis, the total number of distant metastasis events was small. Only five patients (1.3%) in the brachytherapy monotherapy group experienced distant metastases compared with 50 patients (13.3%) who experienced biochemical failure. A Cox regression multivariate analysis of this endpoint showed that only age was significantly related to freedom from distant metastases (Table 4) .
Effect on Toxicity
Differences between treatment group toxicities are shown in Table 5 . Rectal bleeding was defined as a grade ≥2 on the Other specific toxicities were defined as patient-reported experience at any follow-up visit. Among all patients in the present study, those undergoing combination radiotherapy experienced higher urinary toxicity and lower potency than patients receiving brachytherapy without EBRT. Significant differences in toxicity determined by a crosstabs chi-squared analysis include urge incontinence (P < 0.001), haematuria (P < 0.001), dysuria (P < 0.001), and change in quality-of-life IPSS (P = 0.002). Actuarial analysis of patients who were potent before treatment showed that patients receiving combination therapy were more likely to experience loss of potency, as measured by the Mount Sinai erectile function scale (P = 0.040; Fig. 3 ).
There were no significant differences in rectal bleeding, stress incontinence, urinary retention, total IPSS, or potency at last follow-up, as measured by the Mount Sinai erectile function scale. There was also no significant difference in the change from before treatment to last visit in total IPSS, quality-of-life IPSS, SHIM score, or Mount Sinai erectile function score.
Discussion
Prostate cancer is the most prevalent cancer diagnosed in men in the USA, excluding skin cancer [15] . There is currently uncertainty surrounding the optimal treatment for patients with prostate cancer with intermediate-risk features. In the brachytherapy management of prostate cancer, the selection of patients for brachytherapy monotherapy is particularly undefined.
Results from the ASCENDE-RT Trial found a benefit of adding brachytherapy to EBRT compared with EBRT alone in high-tier intermediate-risk patients [16] . Additionally, preliminary results from RTOG 0232, which examined brachytherapy and combination brachytherapy with EBRT in patients with one intermediate-risk factor, found that EBRT does not improve progression-free survival, FfBF or freedom from distant metastases in these patients. Follow-up was short and an older definition of PSA failure (ASTRO) was used. The RTOG study also found that EBRT slightly increased toxicity in patients with one intermediate-risk factor [7] . Findings are consistent with previous studies that found that dose but not the addition of EBRT predicted FfBF [17, 18] . In the present study, EBRT did not improve FfBF or freedom from distant metastases in patients with one intermediate-risk feature. There was a trend in improvement of FfBF in patients with multiple intermediate-risk features who received combination therapy (87% vs 78%; P = 0.092). The inherent selection bias of the present study, as shown by the significant differences noted in Table 1 , could have prevented finding a significant benefit of adding EBRT in this subset. Patients receiving combination therapy tended to be younger, receive a higher BED and be on ADT than those in the brachytherapy monotherapy group.
Overall, in the present study, patients with one and multiple intermediate-risk features had equivalent rates of biochemical failure (P = 0.112) and distant metastases (P = 0.706) at 10-year follow-up in univariate analyses. While it has been established that having multiple risk factors correlates with poorer biochemical and distant control and prostate cancerspecific survival [19, 20] , equivalence in our data could be explained by effective dose escalation, differences in ADT use, as well as patients with multiple intermediate-risk factors being more likely to receive supplementary EBRT (P < 0.001).
The present study also examined patients' quality of life by measuring toxicities associated with implant monotherapy and combination therapy with EBRT in patients with intermediate-risk prostate cancer. As compared with men of a [21] . While urinary symptoms in men treated with brachytherapy largely recover by 1-3 years after treatment, severity early after implantation can be significant for some men [22] [23] [24] . The same study found that higher D90 can delay IPSS recovery. Higher doses were also found to increase the risk of rectal toxicity [2] . In the present study, the toxicity differences identified between the two treatment groups largely refer to toxicities identified at any follow-up visit and were probably temporary. These included urge incontinence, haematuria and dysuria.
We found no difference between the two treatment groups in toxicities measured at last follow-up such as change in potency, IPSS and SHIM score, indicating recovery from at least some treatment side effects. To our knowledge, this is the first study of its size to examine the toxicity of brachytherapy alone or combined with EBRT. It is also the first study to examine the cancer control outcomes of these treatments in patients with multiple intermediate-risk factors.
In conclusion, brachytherapy monotherapy with a BED >150 Gy resulted in equal biochemical control in patients with one and more than one intermediate-risk features as well as distant control in patients with one intermediate-risk feature. While no significant benefit was shown, we believe that the addition of EBRT may prevent recurrence in patients with multiple intermediate-risk features. 
